Synthetic oleanane triterpenoids: Magic bullets or not?

Kidney International

Volumn 83, Issue 5, 2013, Pages 785-787

  Abboud, Hanna E ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BARDOXOLONE METHYL; KELCH LIKE ECH ASSOCIATED PROTEIN 1; MEGALIN; REACTIVE OXYGEN METABOLITE; RTA 405; RTA 450; TRANSCRIPTION FACTOR NRF2; TRITERPENOID; UNCLASSIFIED DRUG;

ALBUMINURIA; CAPILLARY PRESSURE; CHRONIC KIDNEY DISEASE; DIABETIC NEPHROPATHY; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY PLASMA FLOW; MESANGIUM CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; REVIEW; SIDE EFFECT; WEIGHT REDUCTION;

EID: 84877075423     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2013.38     Document Type: Note

References (10)

1. Pergola PE, Raskin P, Toto RD et al. Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med 2011; 365: 327-336.
2. Liby KT, Sporn MB. Synthetic oleanane triterpenoids: multifunctional drugs with a broad range of applications for prevention and treatment of chronic disease. Pharmacol Rev 2012; 64: 972-1003.
3. Jun M, Venkataraman V, Razavian M et al. Antioxidants for chronic kidney disease. Cochrane Database Syst Rev 2012; 10: CD008176. doi:10.1002/14651858. CD008176.pub2.
4. Zheng H, Whitman SA, Wu W et al. Therapeutic potential of Nrf2 activators instreptozotocin-induced diabetic nephropathy. Diabetes 2011; 60: 3055-3066.
5. Upadhyay A, Sarnak MJ, Levey AS. Bardoxolone methyl, chronic kidney disease, and type 2 diabetes. N Engl J Med 2011; 365: 1746.
6. McMahon GM, Forman JP. Bardoxolone methyl, chronic kidney disease, and type 2 diabetes. N Engl J Med 2011; 365: 1746.
7. Wang H, Garvin JL, D'Ambrosio MA et al. Heme oxygenase metabolites inhibit tubuloglomerular feedback in vivo. Am J Physiol Heart Circ Physiol 2011; 300: H1320-H1326.
8. Reisman SA, Chertow GM, Hebbar S et al. Bardoxolone methyl decreases megalin and activates nrf2 in the kidney. J Am Soc Nephrol 2012; 23: 1663-1673.
9. Ding Y, Stidham RD, Bumeister R et al. The synthetic triterpenoid, RTA 405, increases the glomerular filtration rate and reduces angiotensin II-induced contraction of glomerular mesangial cells. Kidney Int 2013; 83: 845-854.
10. Zoja C, Corna D, Nava V et al. Analogues of bardoxolone methyl worsen diabetic nephropathy in rats with additional adverse effects. Am J Physiol Renal Physiol 2012; e-pub ahead of print 7 November 2012.